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Purpose: The primary objective was to assess whether transrectal ultrasound 
(TRUS)-guided prostate biopsy in the left lateral decubitus (LLD) position differed from 
the procedure in the lithotomy position regarding patients’ pain perception. The secon-
dary objective was to assess the analgesic effect of intrarectal 2% lidocaine gel in this 
setting.
Materials and Methods: This single-center, open-label trial enrolled 148 men under-
going prostate biopsy. Then men were randomly assigned to group 1 (LLD position, no 
lidocaine, n=50, “test”), group 2 (lithotomy position+lidocaine, n=50, “positive control”),
and group 3 (lithotomy position, no lidocaine, n=48, “negative control”). Twelve-core 
samples were taken in each biopsy set. Pain was assessed by using a 10-point visual 
analogue scale (VAS). 
Results: Across the groups, patients were comparable regarding age, prostate-specific 
antigen levels, prostate volume, digital rectal examination findings, and pathohisto-
logical diagnosis. VAS scores were lower in group 1 (median, 2.95) than in group 2 
(median, 4.95; p＜0.001) or group 3 (median, 4.60; p＜0.001). The difference between 
group 2 and group 3 was insignificant (p=0.268). The adjusted mean differences (with 
adjustment for the above covariates) were as follows: group 1 vs. group 2, -1.43 (95% 
confidence interval [CI]: -2.25 to -0.60; p＜0.001); group 1 vs. group 3, -1.22 (95% CI: 
-2.04 to -0.41; p=0.001); group 2 vs. group 3, 0.20 (95% CI, -0.63 to 1.04; p=0.836); and 
group 1 vs. groups 2 and 3, -1.33 (95% CI, -1.92 to -0.73; p＜0.001). The procedure was 
comparably well tolerated across the groups.
Conclusions: Pain perception during prostate biopsy was lower in the LLD position than 
in the lithotomy position. Intrarectal 2% lidocaine gel does not seem to affect pain 
perception.
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INTRODUCTION
Prostate carcinoma is one of the most common malignant 
diseases in men. In Croatia, the annual incidence rate has 
been estimated at 79.2/100,000 [1]. Introduction of pros-
tate-specific antigen (PSA) testing and, particularly, 
transrectal ultrasound (TRUS)-guided prostate biopsy 
have greatly improved the detection of prostate cancer [2]. 
Biopsy can be performed in different patient positions, i.e., 
the lithotomy position, the lateral decubitus position, or 
the knee-chest position [3], and typically, 10, 12, or even 
more core samples are taken [4]. Sampling of a greater 
number of biopsy cores causes some degree of discomfort 
or pain in most patients [5,6]. 
One randomized trial indicated that intrarectal applica-
tion of 2% lidocaine gel prior to biopsy was a simple, safe, Korean J Urol 2012;53:87-91
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and effective analgesic method for this purpose [7]. Howev-
er, a recent meta-analysis of 5 other randomized trials com-
paring intrarectal lidocaine gel with a placebo gel or no 
treatment [8] and two subsequent trials comparing lido-
caine gel with no treatment [9,10] failed to detect a pain-re-
lieving effect of this intervention. Also, a recent random-
ized trial suggested that pain perception in patients under-
going prostate biopsy might be less profound in the left lat-
eral decubitus (LLD) position than in the lithotomy posi-
tion [11], whereas another one did not [12].
Our standard procedure has been systematic 12-core 
prostate biopsy in the lithotomy position with the intra-
rectal placement of 10 ml of 2% lidocaine gel 5 minutes prior 
to the procedure. Considering the conflicting reports on 
pain perception in the lateral decubitus vs. lithotomy posi-
tion [11,12] and the analgesic effects of intrarectal anes-
thetic gel [7-10], the primary objective of the present study 
was to evaluate pain perception in patients undergoing 
prostate biopsy in the LLD position compared with the lith-
otomy position, and the secondary objective was to eval-
uate the analgesic effect of intrarectal 2% lidocaine gel.
MATERIALS AND METHODS
1. General design
This prospective, randomized, single-center, open-label 
trial (with blinded data analysis) was performed between 
February 2008 and July 2010 in General Hospital Vara-
zdin, Croatia. Consecutive eligible patients were randomly 
assigned to one of three groups: group 1, biopsy performed 
in the LLD position without topical lidocaine (“test” treat-
ment); group 2, biopsy performed in the lithotomy position 
with intrarectal application of 10 ml of 2% lidocaine gel 5 
minutes before the procedure (our standard procedure, 
“positive control” treatment); and group 3, biopsy per-
formed in the lithotomy position without topical lidocaine 
(“negative control” treatment). 
2. Sample size and randomization
In the five trials embraced by the recent meta-analysis [8] 
and two subsequent trials [9,10], pain scores on a 10-point 
visual analogue scale (VAS) in patients undergoing pros-
tate biopsy with or without intrarectal anesthetic gel aver-
aged between 3 and 5.6 with standard deviations (SDs) be-
tween 1.5 and 2.7. In an analysis of variance with 3 treat-
ment groups, assuming a mean VAS score of 5 under the 
null hypothesis and an SD of 2.5, a total of 126 patients (42 
per group) would provide 81% power at the overall 0.05 al-
pha level to detect a mean difference of 1.5 VAS score points 
between any two treatments. The targeted detectable dif-
ference (1.5 points) was set arbitrarily but accounted for the 
fact that the effect of the periprostatic nerve block vs. place-
bo has been estimated at around 2.1 score points and at 
around 1.5 score points as compared with intrarectal lido-
caine [8]. Considering a possible imprecision of the varia-
bility estimate, we decided to enroll a total of 150 patients 
(50 per group) to ascertain at least 80% power for detection 
of the targeted difference.
The randomization list was generated by using the per-
mutated block method (block size 6) and was concealed 
from the patient-enrolling investigators (confined with a 
registered nurse assisting in the procedure but not partic-
ipating in the study). When a patient met the inclusion and 
exclusion criteria, the assigned treatment was disclosed.
3. Inclusion and exclusion criteria
Inclusion criteria were as follows: 1) indication for a pros-
tate biopsy (elevated PSA or PSA velocity ≥0.75 ng/ml) or 
an abnormal digital rectal finding, 2) no previous prostate 
biopsy, and 3) informed consent. Exclusion criteria were: 
1) concomitant anorectal disease, 2) current treatment 
with analgesics, 3) impaired intellectual ability (inability 
to understand the informed consent), and 4) contra-
indications for the lithotomy position (e.g., hip joint disease 
or a contracture).
4. Biopsy
All biopsies were performed by the same investigator (a 
qualified urologist) on a Siemens Sonoline SL-1 ultrasound 
device with Siemens Endo-P Sonde Biplane, US Biopsy 
18G Biopsyneedle, and Promag 2.2 Automatic Biopsy 
System and were systematic 12-core biopsies (all cores 
were obtained from the lateral areas of the prostate, 2 from 
the base, 2 from the mid-lobe, and 2 from the apex on each 
side). 
Antibiotic prophylaxis (2x500 mg oral ciprofloxacin/day) 
was started the night before the procedure and was ex-
tended for 4 days.
5. Patient assessment
Immediately after the procedure, patients’ pain perception 
was assessed by using a 10-point VAS (0, no pain; 10, excru-
ciating pain). All patients were outpatients and were dis-
charged after a 2-hour post-biopsy observation. They were 
scheduled for a regular visit with urinalysis 7 days after 
biopsy. All other visits or procedures were performed on an 
“as-needed” basis.
6. Statistical analysis
Blinded data analysis was performed by an investigator 
not included in the clinical part of the trial. Considering the 
trial objectives, the comparisons of interest were between 
group 1 (LLD position, “test”) and groups 2 and 3 (lithotomy 
position with or without lidocaine gel, i.e., “positive control” 
and “negative control” control, respectively) and between 
group 2 and group 3. Univariate comparisons were per-
formed by using Kruskal-Wallis nonparametric analysis of 
variance with adjustment for three pair-wise comparisons 
(Dunn’s test). Because in a multivariate analysis (adjust-
ment for age, PSA value, prostate volume, pathohisto-
logical diagnosis, and digital rectal finding), residuals of 
the VAS scores showed a normal distribution, a general lin-
ear model was fitted to the data to obtain adjusted 
(least-square, LS) means and LS-mean differences be-Korean J Urol 2012;53:87-91
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TABLE 1. Patient characteristics
Variable Group 1 (LLD position)
Group 2 (lithotomy 
position+2% lidocaine)
Group 3 (lithotomy 
position, no lidocaine)
Intergroup 
differences
a
No. of patients
Age (yr)
Prostate volume (cm)
PSA (ng/ml)
Pathohistological diagnosis
Benign prostate hypertrophy
Chronic inflammation
ASAP
Carcinoma (Ca detection rate)
Positive digital rectal finding
50
69.3±6.8 (range, 55 to 82)
     30.0 (24.0-43.0)
       8.3 (6.1-13.1)
        15 (30.0)
        12 (26.0)
  0
        22 (44.0)
        22 (44.0)
50
70.3±7.4 (range, 51 to 86)
     36.5 (30.0-49.0)
       8.5 (5.8-20.0)
        15 (30)
        17 (34)
          1 (2.0)
        17 (34.0)
        19 (38.0)
48
69.7±7.4 (range, 54 to 84)
     36.0 (26.0-44.0)
       8.0 (6.2-10.7)
        18 (37.5)
          9 (18.9)
  0
        21 (43.8)
        23 (47.9)
-
p=0.797
p=0.116
p=0.719
p=0.438 (overall)
p=0.607
Values are presented as mean±SD (range), medicine (interquartile range) or number (%).
LLD, left lateral decubitus; ASAP, atypical small acinar proliferation; PSA, prostate-specific antigen.
a: From one-way analysis of variance or a chi-square test.
TABLE 2. Visual analogue scale (VAS) pain scores and univariate comparison among groups
Group 1 (LLD position)
Group 2 (lithotomy 
position+lidocaine)
Group 3 (lithotomy 
position, no lidocaine)
Inter-group differences
a
VAS score 2.95 (2.00-4.53)
(range 0 to 8.00)
4.95 (3.50-5.00)
(range 1.20 to 8.50)
4.60 (3.50-5.00)
(range 0 to 10)
Group 1 vs. 2: z=4.34, p＜0.001
Group 1 vs. 3: z=3.67, p＜0.001
Group 2 vs. 3: z=0.62, p=0.268
Values are presented as median (interquartile range).
p-values are considered significant if ＜0.009 (i.e., z-value ≥2.39).
LLD, left lateral decubitus.
a: From Kruskal-Wallis one-way analysis of variance with adjustment for multiple comparisons (Dunn’s test). 
tween the groups with Tukey-Kramer adjustment for mul-
tiple comparisons. Because the LS-means for group 2 and 
group 3 were practically identical, an additional analysis 
was done in which group 1 (LLD position) was compared 
with groups 2 and 3 cumulatively (lithotomy position). We 
used STATA ver. 9.0 (StataCorp LP, College Station, TX, 
USA) software.
RESULTS
Two patients randomly assigned to group 3 (lithotomy posi-
tion, no lidocaine) decided not to participate in the trial; 
hence, a total of 148 patients were included. Patients in the 
three groups were generally comparable regarding age, 
PSA levels, prostate volume, digital rectal findings, and 
pathohistological diagnosis (Table 1).
In the univariate analysis, VAS pain scores in group 1 
(LLD position, no lidocaine; median, 2.95) were signi-
ficantly lower than in either group 2 (lithotomy posi-
tion+lidocaine; median, 4.95) or group 3 (lithotomy, no lido-
caine; median, 4.60), whereas the difference between 
groups 2 and 3 was insignificant (Table 2).
After adjustment for the factors depicted in Table 1, VAS 
pain scores in group 1 remained significantly lower than 
in group 2 or group 3, whereas there was practically no dif-
ference between group 2 and group 3 (Table 3).
The biopsy was comparably well tolerated across the 
groups. Two patients in group 3 experienced minor rectal 
bleeding during the post-biopsy observational period. One 
patient in group 1 and one in group 3 developed a febrile 
uroinfection, which responded well to antibiotics and sub-
sided within 2 weeks after the procedure. Hematuria was 
observed in 17/50 patients (34%) in group 1, 20/50 patients 
(40%) in group 2, and 15/48 patients (31%) in group 3, all 
resolving within 2 weeks after biopsy. Minor complications 
such as hematospermia were not noted.  
DISCUSSION
TRUS-guided prostate biopsy has greatly improved the di-
agnosis of prostate cancer because it is a highly sensitive 
and specific method that is generally (regardless of the per-
formance modalities) safe and well tolerated [13]. The ma-
jor disadvantages of the procedure are anal discomfort, 
largely due to the insertion of the ultrasound probe; pain, 
predominantly induced by the needle penetration through 
the prostate capsule; and a certain level of psychological 
stress [14], largely related to the nature of the procedure 
(e.g., patient’s position, anal insertion of the probe, the pos-
sibility of a malignant disease). Regarding pain manage-
ment, the guidelines of the European Association of 
Urology suggest periprostatic block as a state of the art Korean J Urol 2012;53:87-91
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TABLE 3. Adjusted mean differences (with 95% confidence intervals, CI) between groups regarding visual analogue scale pain scores 
(multivariate analysis
a)
Comparison Difference (95% CI) p-value
Group 1 (LLD) vs. Group 2 (lithotomy+lidocaine)
Group 1 (LLD) vs. Group 3 (lithotomy, no lidocaine)
Group 2 vs. Group 3
Group 1 (LLD) vs. Group 2 & 3 (lithotomy)
-1.43 (-2.25 to -0.60)
-1.22 (-2.04 to -0.41)
0.20 (-0.63 to 1.04)
-1.33 (-1.92 to -0.73)
＜0.001
0.001
0.836
＜0.001
Mean differences, confidence intervals, and p-values were determined with Tukey-Kramer adjustment for multiple comparisons.
LLD, left lateral decubitus.
a: General linear modelwas fitted to visual analogue scale scores (adjustments: age, prostate-specific antigen, prostate volume, pathohis-
tological diagnosis, and digital rectal finding, all p＞0.100). 
method [13]. Periprostatic block is more effective and appa-
rently at least equally as safe and well tolerated as applica-
tion of topical anesthetic gel or no local analgesic treatment 
[8]. Nevertheless, it may have complications, such as re-
peated injections during the biopsy, systemic lidocaine tox-
icity, urinary incontinence, and, occasionally, degradation 
of the image resolution due to anesthetic injection [15,16]. 
Therefore, other methods may still be considered legit-
imate, particularly because the level of pain induced by the 
biopsy is, at worst, moderate in most patients.
Topical intrarectal application of anesthetic gels (e.g., 
2% lidocaine) has been traditionally considered to relieve 
anal discomfort, but a recent meta-analysis of randomized 
trials [8] and two subsequent trials [9,10] indicated a lack 
of an analgesic effect. The present data are in line with 
these observations. The evaluation of lidocaine gel in the 
present trial would have attained a higher level of evidence 
had we used a placebo gel and a full 2x2 factorial design (i.e., 
combination of patient positions and gel), but this was not 
the primary objective of this study. From the methodo-
logical standpoint (randomization, accounting for poten-
tial confounders), the present observations should be 
viewed as a fair contribution to the body of evidence [8-10] 
indicating a lack of efficacy of topical lidocaine in this 
setting.
The main finding of the present trial is a lower intensity 
of pain in patients undergoing prostate biopsy in the LLD 
position than in the lithotomy position (with or without in-
trarectal lidocaine gel) as assessed on a 10-point VAS im-
mediately after the procedure. By size, the observed ad-
justed differences (around 1.4 score points vs. the lithotomy 
position with 2% lidocaine gel, around 1.2 score points vs. 
the lithotomy position without lidocaine, and around 1.3 
score points vs. cumulative lithotomy position) are similar 
to those between periprostatic nerve block and intrarectal 
anesthetic gel (around 1.5 score points) [8] and should 
therefore be considered practically relevant. Similar ob-
servations were reported from a recent trial in which 340 
patients were randomly assigned to undergo prostate biop-
sy either in the LLD or lithotomy position without further 
topical analgesic treatment [11], but another smaller trial 
(total n=70) [12] reported less pain in the lithotomy position 
than in the LLD position. There appears to be no plausible 
explanation for the discrepancy between the current and 
some of the published [11] vs. other published data [12], ex-
cept for the fact that all three trials were single-center trials 
and that under such conditions, observations in smaller tri-
als could be by chance (due to sampling variability). It 
should be noted, however, that in the present trial the 
“effect of patient position” was consistently significant in 
statistical terms and practically relevant by size in both 
univariate comparisons and after adjustment for poten-
tially relevant covariates. Taken together, the present and 
the published data [11,12] strongly suggest that patients’ 
pain perception during TRUS-guided prostate biopsy in 
the LLD position might be relevantly lower than in the lith-
otomy position, and this topic thus deserves further 
well-designed multicentric evaluations. The present data 
do not allow for a straightforward explanation of the benefi-
cial “effect” of the LLD position. Perception of pain is a high-
ly subjective psychological phenomenon and the methods 
commonly used in this setting (e.g., VAS scoring systems) 
evaluate exactly that-the subjective interpretation of pain-
ful stimuli that may be affected by a number of other psy-
chological phenomena, particularly anxiety and depres-
sion, which are highly prevalent among patients under-
going prostate biopsy [14]. The lithotomy position could be 
more unpleasant or embarrassing than the LLD position, 
and therefore, the pain perception could be intensified; it 
is considered “gynecological” and “exposing” as compared 
to the LLD position, which is a more relaxed, physiological 
position typically used for sleep and rest. Therefore, it could 
be viewed as a stress-relieving position that could be bene-
ficial during this relatively unpleasant procedure. Unfor-
tunately, neither the present nor the published studies 
evaluated the levels of depression or anxiety concomitantly 
with the pain evaluation. We suggest that such evaluations 
in future studies could help us to understand the under-
lying mechanisms of the observed phenomena.
CONCLUSIONS
In conclusion, the present results support the view that the 
subjective perception of pain during prostate biopsy is less Korean J Urol 2012;53:87-91
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profound in patients in the LLD position than in the lith-
otomy position and that intrarectal application of 2% lido-
caine gel has no analgesic effect in this setting. 
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